ClinicalTrials.gg
RecruitingNCT06949423NEST-AUpdated May 15, 2026

Assessing the Impact of dTMS on Neural Targets Associated With Alcohol Use Disorder

An interventional study of Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Active and Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Sham in Alcohol Use Disorder (AUD) and Transcranial Magnetic Stimilation, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Alcoholism by Stanford University — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Stanford University.

Planned enrollment
5th of 11
100 · median 60
Started
2025
with 1 other
No phase
10 of 12
4 open now
Registered
11th of 12
by date

Among the 12 studies in Alcoholism by Stanford University, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 11th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies in Alcoholism by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Alcoholism by Stanford University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of deep transcranial magnetic stimulation as a treatment for Veterans with Alcohol Use Disorder (AUD) to decrease the exceedingly high rate of relapse associated with this condition.

Read the detailed description

Alcohol use disorder (AUD) is a highly prevalent disorder with a chronic relapse-remit cycle, and over 60% of individuals relapse within months of treatment. Preclinical and human research over the last several decades have defined AUD as a neural circuit-based disorder, which are driven by changes in salience network (SN) function. Emerging non-invasive neuromodulation techniques, such as deep transcranial magnetic stimulation (dTMS), can directly modify neural targets that are related to AUD relapse risk, including the SN.

Preclinical and clinical studies have shown that manipulation of deep cortical nodes within the salience network (SN), such as the dorsal anterior cingulate cortex (dACC), can reduce compulsive drinking. Our lab has demonstrated that blunted dACC activation to affective cues predicts relapse - identifying dACC as a promising neuromodulation target. A systematic interrogation of salience network neuromodulation bridges preclinical and clinical research and has the potential to revolutionize AUD treatment. Our preliminary data demonstrates 1) feasibility of the proposed dTMS protocol and 2) promising neural and clinical outcomes. Specifically, those who received this innovative intervention demonstrated increased dACC activation to affective cues from pre- to post-treatment, dynamic changes in functional connectivity and 100% abstinence at follow up.

Building on these data and a theory-driven conceptual framework, the current proposal aims to systematically address three remaining scientific gaps: 1) to what extent does dTMS stimulation of the dACC modify drinking rates and neural targets, 2) can target engagement be a marker of early treatment response, and 3) how long do the effects of dTMS last? This research is significant and innovative as it utilizes a novel, neuromodulation technique to directly manipulate neural networks that drive relapse in AUD.

03

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Transcranial Magnetic Stimilation

Keywords

  • Veterans
  • Deep Transcranial Magnetic Stimulation (dTMS)
  • Neuroimaging
  • Relapse
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75.
  • Current diagnosis of moderate to severe AUD (\≥4 diagnostic symptoms).
  • Ability to obtain a Motor Threshold (MT) will be determined during the screening process.
  • Has an adequately stable condition and environment to enable attendance at scheduled clinic visits.
  • Able to read, understand and voluntarily sign the Form prior to participating in any study-specific procedures or assessments.
  • If on a medication regimen for comorbid symptoms, that regimen will be stable for the duration of the study and patient will be willing to remain on this regimen during the treatment phase.
  • Fluency in English.

Exclusion criteria

Exclusion Criteria:

  • Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) : such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, metal in the head, metal in the body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/objected in the head and body within 30 cm of the treatment coil.
  • General medical condition, disease or neurological disorder that interferes with the assessments or participation.
  • Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.
  • Current substance abuse (except caffeine or nicotine) as determined by positive toxicology screen.
  • Have a mass lesion, cerebral infarct, or other active CNS disease, including an alcohol-related seizure or a seizure disorder.
  • A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.
  • Severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to follow study protocols.
  • Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).
  • Taking benzodiazepine or neuroleptic medications, or any medication known to alter seizure threshold
  • Acute or unstable chronic illness.
  • Current or lifetime history of bipolar disorder or psychosis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Active dTMS

    Participants will receive 30 sessions of active-dTMS to the dACC/mPFC with the H7 coil, administered 3 times per day over 10 consecutive business days. Each treatment visit will last approximately 30 minutes in total.

    Device: Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Active

  • Sham comparator
    Sham dTMS

    Participants will receive 30 sham dTMS sessions, administered 3 times per day over 10 consecutive business days. Each treatment visit will last approximately 30 minutes in total.

    Device: Deep Transcranial Magnetic Stimulation (dTMS) H7 coil - Sham

Interventions

  • DeviceDeep Transcranial Magnetic Stimulation (dTMS) H7 coil - Active

    The study will utilize the H7 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.

  • DeviceDeep Transcranial Magnetic Stimulation (dTMS) H7 coil - Sham

    The study will utilize an identical protocol using the H7 coil to administer a sham condition.

06

What researchers measure

Primary outcomes

  1. Change in Dorsal Anterior Cingulate Cortex Function (dACC) Activation During the FACES Task, Measured via fMRI

    dACC activation to threat faces will be measured using fMRI during the FACES task, designed to assess emotional processing. Activation will be quantified as percent signal change from baseline (pre-treatment) to post-treatment scan.

    Time frame: 1-4 days post treatment

  2. Percentage of Days Abstinent from Alcohol, Assessed by Timeline Followback (TLFB)

    Alcohol abstinence will be assessed using the TLFB structured interview method. The outcome will be calculated as the percentage of alcohol-free days out of the total number of days in the 3-month follow-up period post-treatment.

    Time frame: 3-months post treatment

  3. Percentage of Heavy Drinking Days, Assessed by Timeline Followback (TLFB)

    Heavy drinking days are defined as ≥5 drinks/day for men and ≥4 drinks/day for women within a 2-hour period. Self-reported data via TLFB used to calculate the percentage of heavy drinking days during the 3-month follow-up treatment.

    Time frame: 3 months post-treatment

Secondary outcomes

  1. Change in Salience Network Functional Connectivity During FACES Task, Measured via fMRI

    Functional connectivity between the dACC and prefrontal cortex (PFC) will be assessed using fMRI during the FACES Task. Connectivity strength will be calculated using psychophysiological interaction (PPI) analysis or similar methods.

    Time frame: 1-4 days post treatment

  2. Change in Resting-State Salience Network Activation, Measured via fMRI

    Resting-state fMRI will assess dACC activation. Measures will include percent signal change pre- to post-treatment.

    Time frame: 1-4 days post-treatment

  3. Change in Resting-State Salience Network Functional Connectivity, Measured via fMRI

    Resting-state functional connectivity between the dACC and prefrontal cortex (PFC) will be measured using CONN.

    Time frame: 1-4 days post treatment

  4. Relapse Status, assessed by Timeline Followback (TLFB)

    Relapse will be defined as any alcohol use following the post-treatment period, assessed using TLFB. Outcome will be reported as a binary (yes/no) variable.

    Time frame: 3 months post-treatment

  5. Total Number of Alcoholic Drinks Consumed, Assessed by Timeline Followback (TLFB)

    Self-reported alcohol use over the 3-month follow-up period will be assessed via TLFB, and the total number of standard alcoholic drinks consumed will be calculated and reported.

    Time frame: 3 months post-treatment

07

Study locations

1 of 1 sites recruiting
  • VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
    Recruiting
    • Eileen G Fischer, BS · Contactgrace.fischer@stanford.edu · 210-993-2065
    • Claudia B Padula, PhD · Principal investigator
    • Michelle R Madore, PhD · Principal investigator
08

References and documents

Publications

  • Padula CB, Tenekedjieva LT, McCalley DM, Al-Dasouqi H, Hanlon CA, Williams LM, Kozel FA, Knutson B, Durazzo TC, Yesavage JA, Madore MR. Targeting the Salience Network: A Mini-Review on a Novel Neuromodulation Approach for Treating Alcohol Use Disorder. Front Psychiatry. 2022 May 17;13:893833. doi: 10.3389/fpsyt.2022.893833. eCollection 2022. PubMed 35656355 ↗
  • Padula CB, Tenekedjieva LT, McCalley DM, Morales JM, Madore MR. Accelerated deep TMS in alcohol use disorder: A preliminary pilot trial targeting the dorsal anterior cingulate cortex increases neural target engagement and abstinence. Brain Stimul. 2024 Sep-Oct;17(5):1098-1100. doi: 10.1016/j.brs.2024.09.002. Epub 2024 Sep 13. No abstract available. PubMed 39265786 ↗
  • Harel M, Perini I, Kampe R, Alyagon U, Shalev H, Besser I, Sommer WH, Heilig M, Zangen A. Repetitive Transcranial Magnetic Stimulation in Alcohol Dependence: A Randomized, Double-Blind, Sham-Controlled Proof-of-Concept Trial Targeting the Medial Prefrontal and Anterior Cingulate Cortices. Biol Psychiatry. 2022 Jun 15;91(12):1061-1069. doi: 10.1016/j.biopsych.2021.11.020. Epub 2021 Dec 6. PubMed 35067356 ↗
  • Peters SK, Dunlop K, Downar J. Cortico-Striatal-Thalamic Loop Circuits of the Salience Network: A Central Pathway in Psychiatric Disease and Treatment. Front Syst Neurosci. 2016 Dec 27;10:104. doi: 10.3389/fnsys.2016.00104. eCollection 2016. PubMed 28082874 ↗
  • Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010 Jan;35(1):217-38. doi: 10.1038/npp.2009.110. PubMed 19710631 ↗

Individual participant data

Plan to share: Yes — Any data, specimens, forms, reports, and other records that leave the site will be identified only by a participant ID number to maintain confidentiality. The ID Number will have no relationship to any aspect of identifiable private information. Therefore, the data associated with each participant will be completely de-identified and there will be no mechanism by which users can re-identify participant data (e.g., name, address) with the subject code.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Three to twelve months after publication.

Access criteria: Researchers who provide a methodologically sound proposal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2030, 54 months after the start.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 54 months is above that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 29, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06949423
Responsible party
Claudia Padula (Assistant Professor, Stanford University) — Principal investigator
First posted
Apr 29, 2025
Start date
Dec 17, 2025
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
May 15, 2026

Study contacts

Samantha J Ward, BS
Contact
samward@stanford.edu
650-493-5000 ext. 64975
Eileen G Fischer, BS
Contact
grace.fischer@stanford.edu
210-993-2065
Claudia B Padula, PhD
principal investigator · Stanford University
Michelle R Madore, PhD
principal investigator · Stanford University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion